Share this article
Share this article
ResearchAndMarkets.com s offering.
Sepsis was killing over 30 million people a year with no definitive diagnostic in hand. And now the COVID-19 Pandemic has increased the sepsis death toll. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life-saving diagnostics can command a premium in the market, especially deaths related to COVID-19 infections. Understand the different drivers of this huge global diagnostic market and where the opportunity lies.